ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

被引：513

作者：

Colombo, N. ^{[1
,23
,24
]}

Sessa, C. ^{[2
,56
]}

du Bois, A. ^{[3
,30
]}

Ledermann, J. ^{[4
,39
]}

McCluggage, W. G. ^{[5
,42
]}

McNeish, I. ^{[6
,43
]}

Morice, P. ^{[7
,18
]}

Pignata, S. ^{[8
,51
]}

Ray-Coquard, I. ^{[9
,52
]}

Vergote, I. ^{[10
,11
,64
,65
]}

Baert, T. ^{[3
,15
]}

Belaroussi, I. ^{[7
,18
]}

Dashora, A. ^{[12
,28
]}

Olbrecht, S. ^{[10
,11
,47
,48
]}

Planchamp, F. ^{[13
,50
]}

Querleu, D. ^{[14
,50
]}

Baert, T. ^{[3
,15
]}

Banerjee, S. ^{[16
,17
]}

Belaroussi, I. ^{[7
,18
]}

Blecharz, P. ^{[19
]}

Bruchim, I. ^{[20
]}

Cibula, D. ^{[21
,22
]}

Colombo, N. ^{[1
,23
,24
]}

Concin, N. ^{[25
]}

Davidson, B. ^{[26
,27
]}

Dashora, A. ^{[12
,28
]}

Devouassoux-Shisheboran, M. ^{[29
]}

du Bois, A. ^{[3
,30
]}

Ferrero, A. ^{[31
]}

Glasspool, R. ^{[32
,33
]}

Gonzalez-Martin, A. ^{[34
]}

Heinzelmann-Schwarz, V. ^{[35
]}

Joly, F. ^{[36
]}

Kim, J. W. ^{[37
]}

Kridelka, F. ^{[38
]}

Ledermann, J. ^{[4
,39
]}

Lorusso, D. ^{[40
]}

Mahner, S. ^{[41
]}

McCluggage, W. G. ^{[5
,42
]}

McNeish, I. ^{[6
,43
]}

Mikami, M. ^{[44
]}

Mirza, M. R. ^{[45
]}

Morice, P. ^{[7
,18
]}

Nicum, S. ^{[46
]}

Olbrecht, S. ^{[10
,11
,47
,48
]}

O'Donnell, D. M. ^{[49
]}

Pautier, P. ^{[18
]}

Planchamp, F. ^{[13
,50
]}

Pignata, S. ^{[8
,51
]}

Querleu, D. ^{[14
,50
]}

机构：

[1] Univ Milano Bicocca, European Inst Oncol IRCCS, Div Med Gynecol Oncol, Milan, Italy

[2] Osped San Giovanni Bellinzona, Oncol Inst Southern Switzerland, Dept Med Oncol, Bellinzona, Switzerland

[3] Kliniken Essen Mitte, Dept Gynecol & Gynecol Oncol, Essen, Germany

[4] UCL Canc Inst, Dept Oncol & Canc Trials, London, England

[5] Belfast Hlth & Social Care Trust, Dept Pathol, Belfast, Antrim, North Ireland

[6] Imperial Coll, Dept Surg & Canc, London, England

[7] Gustave Roussy Canc Campus, Dept Gynecol Surg, Villejuif, France

[8] Ist Nazl Tumori IRCCS Fdn G Pascale, Div Med Oncol, Dept Urogynaecol Oncol, Naples, Italy

[9] Ctr Leon Berard, Dept Med & Surg Oncol, Lyon, France

[10] Leuven Canc Inst, Dept Gynaecol Oncol, Leuven, Belgium

[11] Univ Hosp Leuven, Dept Obstet & Gynecol, Leuven, Belgium

[12] Maidstone & Tunbridge Wells NHS Trust, Dept Cellular Pathol, Tunbridge Wells, Kent, England

[13] Inst Bergonie, Clin Res Unit, Bordeaux, France

[14] Inst Bergonie, Dept Surg, Bordeaux, France

[15] Kliniken Essen Mitte, Essen, Germany

[16] Royal Marsden NHS Fdn Trust, London, England

[17] Inst Canc Res, London, England

[18] Gustave Roussy Canc Campus, Villejuif, France

[19] M Sklodowska Curie Inst, Ctr Oncol, Krakow, Poland

[20] Hillel Yaffe Med Ctr, Gynecol Oncol Unit, Hadera, Israel

[21] Charles Univ Prague, Fac Med 1, Prague, Czech Republic

[22] Gen Univ Hosp, Prague, Czech Republic

[23] European Inst Oncol IRCCS, Milan, Italy

[24] Univ Milano Bicocca, Milan, Italy

[25] Med Univ Innsbruck, Innsbruck, Austria

[26] Norwegian Radium Hosp, Oslo Univ Hosp, Dept Pathol, Oslo, Norway

[27] Univ Oslo, Inst Clin Med, Fac Med, Oslo, Norway

[28] Maidstone & Tunbridge Wells NHS Trust, Tunbridge Wells, Kent, England

[29] Hosp Civils Lyon, Lyon, France

[30] Kliniken Essen Mitte, Essen, Germany

[31] Mauriziano Hosp, Turin, Italy

[32] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[33] Univ Glasgow, Glasgow, Lanark, Scotland

[34] Univ Navarra Clin, Madrid, Spain

[35] Univ Hosp Basel, Gynecol Canc Ctr, Basel, Switzerland

[36] Ctr Francois Baclesse, Caen, France

[37] Seoul Natl Univ, Coll Med, Seoul, South Korea

[38] CHU Sart Tilman Notre Dame Bruyeres, Chenee, Belgium

[39] UCL Canc Inst, London, England

[40] Fdn Policlin Univ A Gemelli IRCCS, Rome, Italy

[41] Ludwig Maximilians Univ Hosp, Univ Hosp, Dept Obstet & Gynaecol, Munich, Germany

[42] Belfast Hlth & Social Care Trust, Belfast, Antrim, North Ireland

[43] Imperial Coll, London, England

[44] Tokai Univ, Sch Med, Hiratsuka, Kanagawa, Japan

[45] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark

[46] Canc Ctr, Oxford, England

[47] Leuven Canc Inst, Leuven, Belgium

[48] Univ Hosp Leuven, Leuven, Belgium

[49] St James Hosp, Dublin, Ireland

[50] Inst Bergonie, Bordeaux, France

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷 / 05期

关键词：

ovarian cancer; adjuvant treatment; surgery; pathology; molecular biology; recurrent disease; GRADE SEROUS CARCINOMA; RANDOMIZED PHASE-III; PLATINUM-BASED CHEMOTHERAPY; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; ADVANCED EPITHELIAL OVARIAN; CLEAR-CELL-CARCINOMA; TERM-FOLLOW-UP; FERTILITY-SPARING SURGERY; PATIENT-REPORTED OUTCOMES; PRIMARY SITE ASSIGNMENT;

D O I：

10.1093/annonc/mdz062

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The development of guidelines recommendations is one of the core activities of the European Society for Medical Oncology (ESMO) and European Society of Gynaecologial Oncology (ESGO), as part of the mission of both societies to improve the quality of care for patients with cancer across Europe. ESMO and ESGO jointly developed clinically relevant and evidence-based recommendations in several selected areas in order to improve the quality of care for women with ovarian cancer. The ESMO-ESGO consensus conference on ovarian cancer was held on 12-14 April 2018 in Milan, Italy, and comprised a multidisciplinary panel of 40 leading experts in the management of ovarian cancer. Before the conference, the expert panel worked on five clinically relevant questions regarding ovarian cancer relating to each of the following four areas: pathology and molecular biology, early-stage and borderline tumours, advanced stage disease and recurrent disease. Relevant scientific literature, as identified using a systematic search, was reviewed in advance. During the consensus conference, the panel developed recommendations for each specific question and a consensus was reached. The recommendations presented here are thus based on the best available evidence and expert agreement. This article presents the recommendations of this ESMO-ESGO consensus conference, together with a summary of evidence supporting each recommendation.

引用

页码：672 / 705

页数：34

共 309 条

[1] Ovarian mass-differentiating benign from malignant: the value of the International Ovarian Tumor Analysis ultrasound rules [J].

Abramowicz, Jacques S. ;

Timmerman, Dirk .

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2017, 217 (06) :652-660

[2]

Afsar B, 2018, NEW ENGL J MED, V378, P1362, DOI 10.1056/NEJMc1802033

[3] Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer [J].

Aghajanian, Carol ;

Goff, Barbara ;

Nycum, Lawrence R. ;

Wang, Yan V. ;

Husain, Amreen ;

Blank, Stephanie V. .

GYNECOLOGIC ONCOLOGY, 2015, 139 (01) :10-16

[4] OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [J].

Aghajanian, Carol ;

Blank, Stephanie V. ;

Goff, Barbara A. ;

Judson, Patricia L. ;

Teneriello, Michael G. ;

Husain, Amreen ;

Sovak, Mika A. ;

Yi, Jing ;

Nycum, Lawrence R. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) :2039-2045

[5] Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer [J].

Alberts, DS ;

Liu, PY ;

Hannigan, EV ;

OToole, R ;

Williams, SD ;

Young, JA ;

Franklin, EW ;

ClarkePearson, DL ;

Malviya, VK ;

DuBeshter, B ;

Adelson, MD ;

Hoskins, WJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) :1950-1955

[6] Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer? [J].

Aletti, Giovanni D. ;

Long, Harry J. ;

Podratz, Karl C. ;

Cliby, William A. .

GYNECOLOGIC ONCOLOGY, 2007, 104 (01) :212-216

[7] BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group [J].

Alsop, Kathryn ;

Fereday, Sian ;

Meldrum, Cliff ;

deFazio, Anna ;

Emmanuel, Catherine ;

George, Joshy ;

Dobrovic, Alexander ;

Birrer, Michael J. ;

Webb, Penelope M. ;

Stewart, Colin ;

Friedlander, Michael ;

Fox, Stephen ;

Bowtell, David ;

Mitchell, Gillian .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) :2654-2663

[8]

[Anonymous], 2016, BMJ

[9]

[Anonymous], 2013, Gynecologic Oncology

[10]

[Anonymous], 2000, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001219

← 1 2 3 4 5 6 7 8 9 10 →